Mark Roschewski, M.D.
Dr. Roschewski is an Associate Research Clinician and the Clinical Director of the Lymphoid Malignancies Branch (LYMB) of the Center for Cancer Research. His research team focuses on the management of aggressive B-cell lymphomas including diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), mantle cell lymphoma (MCL), and primary CNS lymphomas (PCNSL). Recent studies from NCI show that dose-adjusted EPOCH-R is highly effective for adults with BL and specific subtypes of DLBCL such as primary mediastinal B-cell lymphoma. The LYMB research team also recently demonstrated that targeted agents such as ibrutinib are highly effective when combined with chemotherapy in relapsed and refractory PCNSL. Dr. Roschewski has also pioneered an active translational program focused on studying clonal evolution in follicular lymphoma (FL) with an aim of identifying the molecular biology of FL patients who are failed by current chemotherapy. The FL translational program in the LYMB has multiple clinical studies of targeted agents for FL patients who do not yet require therapy as well as multiple treatment studies for patients in need of frontline or relapsed therapy. An important research focus of the LYMB research team involves developing more effective non-invasive methods of monitoring disease activity in patients with lymphoma, including minimal residual disease assays such as circulating tumor DNA. The LYMB research team also is dedicated to developing novel therapies for patients with rare lymphoma subtypes including EBV-associated lymphomas and rare lymphomas that secondarily involve the CNS.
A Phase 2 Study of Response-Adapted Therapy with Copanlisib and Rituximab in Untreated Follicular Lymphoma #xD;Open - Not yet RecruitingNCI Protocol ID NCI-19-C-0030Investigator Mark Roschewski, M.D.
PRISM: A Platform protocol for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin's LymphomaOpen - RecruitingNCI Protocol ID NCI-18-C-0130Investigator Mark Roschewski, M.D.
A Phase 1b/2 Trial of Hu5F9-G4 in Combination with Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin's LymphomaOpen - RecruitingNCI Protocol ID NCI-17-C-0164Investigator Mark Roschewski, M.D.
Phase 2 Trial of Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and other Extranodal Diffuse Large B-cell Lymphomas#xD;Open - RecruitingNCI Protocol ID NCI-17-C-0149Investigator Mark Roschewski, M.D.
Phase 2 Trial of Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-Hodgkin LymphomasOpen - RecruitingNCI Protocol ID NCI-17-C-0125Investigator Mark Roschewski, M.D.Share this trial: Referral Contacts
Contact Name Phone Number Maureen Edgerly 240-760-6013
Open - RecruitingNCI Protocol ID NCI-17-C-0105Investigator Mark Roschewski, M.D.
Phase 1 Study of Ibrutinib and Immuno-chemotherapy using Dose-Adjusted-Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, Rituximab (DA-TEDDI-R) in Primary CNS LymphomaOpen - RecruitingNCI Protocol ID NCI-14-C-0157Investigator Mark Roschewski, M.D.Share this trial: Referral Contacts
Contact Name Phone Number Nicole Lucas 240.760.6252
Open - RecruitingNCI Protocol ID NCI-12-C-0193Investigator Mark Roschewski, M.D.Share this trial: Referral Contacts
Contact Name Phone Number Nicole Lucas 240.760.6252
Open - RecruitingNCI Protocol ID NCI-01-C-0030Investigator Mark Roschewski, M.D.Share this trial: Referral Contacts
Contact Name Phone Number Peggy Shovlin 240.760.6089
Open - RecruitingNCI Protocol ID NCI-94-C-0074Investigator Mark Roschewski, M.D.
Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Adults and Children with Previously Untreated Patients with Aggressive Non-Hodgkin's LymphomaOpen - RecruitingNCI Protocol ID NCI-93-C-0133Investigator Mark Roschewski, M.D.
Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study.Lancet Oncology. 16(5): 541-9, 2015. [ Journal Article ]
- Blood. 127(25): 3127-32, 2016. [ Journal Article ]
- Nat Rev Clin Oncol. 11(1): 12-23, 2014. [ Journal Article ]
- Cancer Cell. 31(6): 833-843, 2017. [ Journal Article ]
- Best Pract Res Clin Haematol. 25(1): 75-89, 2012. [ Journal Article ]
Dr. Mark Roschewski received his B.A. from the University of Notre Dame in 1997 and his M.D. from the University of Nebraska Medical Center in Omaha in 2001. He completed internal medicine residency training while serving in the U.S. Army and completed his hematology-oncology fellowship in 2009 at Walter Reed Army Medical Center (WRAMC) in Washington, DC. He served as the Director of Hematologic Diseases at WRAMC for 3 years before joining the NIH as a Commissioned Corps officer in the United States Public Health Service in 2013. Dr. Roschewski's current role is as an associate resesarch clinician in the Lymphoid Malignancies Branch with a clinical research focus on the biology and managment of patients with both indolent and aggressive forms of non-Hodgkin's lymphoma.
|Lydia Chou C.R.N.P.||Nurse Practitioner|
|Candis Morrison N.P.||Clinical Collaborator|
|Saleema Osman||Patient Care Coordinator (Contr.)|